Using SMYD3 as a target protein, we implemented our screening methodology and report a novel small molecule SMYD3 inhibitor (Inhibitor-4) that impairs breast cancer cell proliferation without affecting normal cells, illustrating the potential of SMYD3 inhibitors in the clinical management of breast cancer as well as a proof of concept for this drug development platform. Here, SMYD3 is linked to breast cancer.